|
|||||
 |
|||||
|
|
Press Releases
February 20, 2012
Genervon Biopharmaceuticals (www.genervon.com) proposes multiple grand challenges to provide biological drugs to meet many unmet critical medical needs of the world. Hundreds of thousands of scientists/clinicians have devoted their lives to research and understand the diseases or disorders in their field of specialization. While they have become experts on the indication(s) they are studying, most of them cannot find a cure. Even big Pharma is not very successful at finding drug candidates in many areas. Genervon has discovered and developed new classes of novel master regulators biological drugs. These proprietary new classes of biological drugs are high level, fetal stage, endogenous master regulators that modulate multiple pathways of gene expression useful to treat disorders and diseases in the nervous system and vascular system. Beyond these indications, Genervon is actively evaluating other diseases and indications such as cardiovascular, oncology, hematology and others not yet in the public domain. Genervon has obtained USA FDA approval to proceed with Phase II clinical trials for two CNS neuro-regeneration and neuro-protection indications. In order to fully exploit the potential of Genervon's proprietary master regulators biological drugs discoveries and dramatically accelerate the drug approval process, Genervon is proposing the G2C to qualified scientists/clinicians to propose more indications and trial protocols for drug approvals. G2C is seeking scientists/clinicians to propose clinical trial Phase II protocols for the indication(s) they are specialized in and to propose preclinical studies protocols for the establishment of proof of concept. If the proposals and credentials are accepted by Genervon, the scientist/clinician will be given novel master regulator drug candidates appropriate for the study of the proposed indication to generate sufficient data from preclinical studies to allow Genervon to obtain IND approval*. The scientist/clinician is also to guide and support clinical trials conducted by Genervon to final approval*. US$1M will be awarded for each indication to each winning scientist/clinician after final Genervon and FDA approval to market the associated drug. US$100k will be awarded to each successful referral approved by Genervon. Orphan drug indications are welcome. Contact: grandchallenges@genervon.com |
| Copyright © 2012 Genervon Biopharmaceuticals, LLC. All rights reserved. All other trademarks or trade names are the property of their respective holders. |